This roundtable series covers treatment of diffuse tenosynovial giant cell tumors with systemic therapy.

Targeting CSF1 Receptor to Manage Tenosynovial Giant Cell Tumor

Adverse Event Burden Tips TKI Selection in Recurrent Diffuse TGCT

Adverse Event Burden Tips TKI Selection in Recurrent Diffuse TGCT

September 11, 2026

During a live event, Seth M. Pollack, MD, and participants discussed how the practical burden of toxicity monitoring is increasingly steering the choice between systemic therapies for recurrent diffuse tenosynovial giant cell tumor.